Terminal / Weight Loss

Survodutide

Phase 3

aka BI 456906

Dual GLP-1/glucagon agonist in phase 3 for obesity and fatty liver.

Mechanism

Activates GLP-1 and glucagon receptors: appetite down, energy expenditure up. The glucagon arm is also why it's being pushed hard for MASH, the serious fatty-liver disease.

Regulatory & Safety Status

Investigational (Boehringer Ingelheim and Zealand Pharma). Not approved.

Research

2026Diabetes, obesity & metabolism

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

2026Therapeutic advances in gastroenterology

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

2026The New England journal of medicine

Survodutide Once Weekly for the Treatment of Adults with Obesity

2026Nature medicine

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

2024PubMed

Latest survodutide research

Related Compounds

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.

Weight Loss

Tirzepatide

Approved

Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.